Floatz logo

Carboplatin

Long COVID

Universita di VeronaSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

25 Active assets in the Long COVID cohort.

Asset / SponsorPhaseRating
RITONAVIR
Kanecia Obie Zimmerman
Phase 2BB
MELATONIN
Duke University
Phase 2B
Rapamycin
Icahn School of Medicine at Mount Sinai
Phase 3B
Paxlovid
Kanecia Obie Zimmerman
Phase 2B
Nirmatrelvir
Kanecia Obie Zimmerman
Phase 2B

View all 25 →

Same molecule, other indications

Carboplatin is also rated in:

lung large cell carcinomaDormant
A
Indicative ·
80 / 100
View asset →
non-small cell squamous lung carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
primary peritoneal carcinomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →